Description
Aspirin is widely used for secondary prevention in cardiovascular disease, but the clinical impact of enteric-coated vs uncoated formulations remains debated. A secondary analysis of the ADAPTABLE trial found no significant difference in major cardiovascular outcomes or bleeding risk between enteric-coated and uncoated aspirin in over 10,000 patients with atherosclerotic cardiovascular disease. Regardless of dose, neither formulation showed superiority in preventing myocardial infarction, stroke, or death. While enteric-coated aspirin is often preferred to reduce gastrointestinal side effects, this study found no clear safety advantage, underscoring the need for further research into its clinical benefit.